{"groups":[{"description":"Participants received PF-06801591 0.5 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 1186 days)","id":"FG000","title":"Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])"},{"description":"Participants received PF-06801591 1 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 659 days)","id":"FG001","title":"Part 1: PF-06801591 1 mg/kg (IV)"},{"description":"Participants received PF-06801591 3 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 1606 days)","id":"FG002","title":"Part 1: PF-06801591 3 mg/kg (IV)"},{"description":"Participants received PF-06801591 10 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 445 days)","id":"FG003","title":"Part 1: PF-06801591 10 mg/kg (IV)"},{"description":"Participants received PF-06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 419 days)","id":"FG004","title":"Part 1: PF-06801591 300 mg (Subcutaneously [SC])"},{"description":"Participants with NSCLC received PF-06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 851 days)","id":"FG005","title":"Part 2: PF-06801591 300 mg (SC) for NSCLC"},{"description":"Participants with UC received PF- 06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 841 days)","id":"FG006","title":"Part 2: PF-06801591 300 mg (SC) for UC"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"9"},{"groupId":"FG005","numSubjects":"32"},{"groupId":"FG006","numSubjects":"21"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"20"},{"groupId":"FG006","numSubjects":"7"}],"type":"Participant refused further follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"4"},{"groupId":"FG006","numSubjects":"5"}],"type":"Other"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"8"},{"groupId":"FG003","numSubjects":"7"},{"groupId":"FG004","numSubjects":"15"},{"groupId":"FG005","numSubjects":"68"},{"groupId":"FG006","numSubjects":"39"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"8"},{"groupId":"FG003","numSubjects":"7"},{"groupId":"FG004","numSubjects":"15"},{"groupId":"FG005","numSubjects":"68"},{"groupId":"FG006","numSubjects":"38"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"10"},{"groupId":"FG006","numSubjects":"5"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"13"},{"groupId":"FG005","numSubjects":"58"},{"groupId":"FG006","numSubjects":"34"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A total of 147 participants were enrolled in this study, and 146 participants received study treatment. For Part 1, 40 participants were enrolled and treated. For Part 2, 107 participants were enrolled including 68 participants with non small cell lung cancer (NSCLC) and 39 participants with urothelial carcinoma (UC), and 106 participants received study treatment."}